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Chromosomal instability (CIN) represents a major hallmark of cancer and is defined 
as the perpetual gain or loss of whole chromosomes during mitotic cell division. It is 
thought that CIN can drive tumor cell evolution by contributing to the generation of 
genetic heterogeneity in cancer. Importantly, tumor evolution might also fuel therapy 
resistance, a major problem for cancer patients in the clinic. However, whether CIN 
contributes directly to the generation of therapy resistance is unclear. So far it was not 
possible to systematically investigate the role of CIN and perpetual mitotic 
chromosome missegregation for the development of therapy resistance due to the fact 
that CIN could not be suppressed in chromosomally instable cancer cells. However, 
most recently, our lab has established means to correct an important molecular trigger 
for CIN in colorectal cancer (CRC) cells, namely increased microtubule dynamics 
during mitosis. In this way, it became possible to suppress chromosome 
missegregation and the evolvement of aneuploidy in otherwise chromosomally 
instable CRC cells. This now opens the possibility to investigate the role of CIN in 
therapy response, which was the aim of this study. 
I used various cell systems to compare the therapy response towards commonly used 
chemotherapeutic drugs in isogenic CIN and non-CIN cells. These include 
chromosomally instable CRC cells, in which CIN was suppressed by treatment with 
low doses of Taxol or by partial suppression of the microtubule polymerase 
chTOG/CKAP5. In addition, CIN was induced in chromosomally stable CRC cells by 
Aphidicolin treatment mediated replication stress or by inhibition of the mitotic 
spindle assembly checkpoint kinase Mps1. CIN and non-CIN cells were treated with 
Oxaliplatin, Cisplatin, 5-FU, Adriamycin, and Irinotecan. I found an increased 
resistance towards Oxaliplatin only in CIN cells with CHK2 deficiency. Other CIN 
cells (e.g. SW620, chromosomally stable HCT116 cells treated by Aphidicolin or 
MPS1-IN-3) did not show any response differences compared with non-CIN cells. 
These results might indicate the CIN phenotype per se does not confer drug resistance, 
but loss of CHK2 function itself might contribute to the drug resistance. 
 







1.1. The eukaryotic cell cycle 
The cell cycle is an accurate and ordered process, during which a parental cell 
replicates its genome and distributes the copies evenly onto two daughter cells. This 
process is divided into two stages: interphase and mitosis. Interphase comprises three 
distinct phases: gap-phase 1 (G1) phase, synthesis (S) phase, and G2 phase. Mitosis 
consists of five distinct phases: prophase, prometaphase, metaphase, anaphase and 
telophase (Vermeulen et al. 2003) (Figure 1-1). 
 
 
Figure 1-1  The eukaryotic cell cycle. 
The eukaryotic cell cycle is divided into G1-, S-, G2, and M phase. M phase is further 
subdivided into prophase, prometaphase, metaphase, anaphase and telophase. Cells 
can exit the cell cycle and enter a resting state called G0.（Figure is modified from 
Vermeulen et al., 2003, p. 132） 






The G1 and G2 phases of the cell cycle are “gap phases” that occur between the two 
main events of the cell cycle, DNA synthesis and mitosis. In G1 phase the cells 
prepare for DNA replication. When the extracellular environment lack of nutrient 
supply or during differentiation, the cells can exit the cell cycle to enter the resting G0 
phase. Upon certain proliferative stimuli, the cells enter G1 and proceed into S phase, 
during which the DNA as well as the centrosomes are duplicated. Once the DNA 
replication is achieved, cells enter mitosis. During prophase, chromatin is condensed 
and chromosomes become visible. At this stage, each chromosome consists of two 
sister chromatids that are attached to each other at the centromere. The nuclear 
envelope breaks down, and the mitotic spindle is assembled during prometaphase. In 
addition, the kinetochores assemble at the centromeric region of the sister chromatids, 
thereby providing binding sites for the microtubules. Firstly, the chromosomes are 
randomly attached to microtubules in a process called “search and capture” (Heald et 
al. 1996). Then they are aligned on the metaphase plate during mitosis (Caspersson et 
al. 1968). During early anaphase, cohesion protein complexes that link the sister 
chromatid are cleaved by separase (Abrieu et al. 2001; Nakajima et al. 2007). Due to 
microtubule shortening, the sister chromatids are separated and move towards the 
spindle poles. The two spindle poles move apart during late anaphase (Saxton and 
McIntosh 1987). During telophase, two new daughter nuclei are formed, and during 
cytokinesis, the separation of the daughter cells is completed by cleavage of the 
cytoplasm (Terada et al. 1998). 
 
1.2. Mitotic spindle assembly and the mitotic spindle assembly 
checkpoint  
The mitotic spindle is a self-organized and dynamic macromolecular structure, which 
is composed of microtubules (MTs), MT-associated proteins and motor proteins. 
Mitotic spindle assembly is dependent on the highly regulated nucleation of MTs 
(Prosser and Pelletier 2017). Three broad categories of MTs exist within a mitotic 
spindle: kinetochore MTs (K-MTs), astral MTs (A-MTs) and inter-polar MTs 
(IP-MTs) (Dumont and Mitchison 2009). K-MTs attach the chromosome to spindle 
poles via the kinetochores. A-MTs radiate from the spindle poles and interact with the 





cell cortex, which is crucial for spindle positioning (Khodjakov et al. 2000; McNally 
2013). IP-MTs originate from opposite poles, which helps to separate the poles and 
stabilizes the spindle (Prosser and Pelletier 2017).  
During chromosome alignment MTs act in a highly dynamic manner and constantly 
change from a growing to a shrinking state. This characteristic of MTs is known as 
“dynamic instability” (Mitchison and Kirschner 1984). A major regulator of MT 
growth is the MT polymerase ch-TOG/CKAP5, which resides at the growing plus tips 
of the MTs and act as a MT stabilizer (Al-Bassam and Chang 2011; Tournebize et al. 
2000). 
Before cells initiate sister chromatid segregation during anaphase, each chromosome 
has to be aligned at the metaphase plate. This is ensured by a signaling pathway known 
as the spindle assembly checkpoint (SAC) (Musacchio and Salmon 2007; Sacristan 
and Kops 2015). The SAC comprises several kinetochore-based proteins including 
Mad1, Mad2, Bub1, BubR1 and the Mps1 kinase (Foley and Kapoor 2013). The SAC 
is activated in response to unattached kinetochores that are present when chromosomes 
are not properly aligned at the metaphase plate. In turn, the SAC inhibits the ubiquitin 
ligase activity of the anaphase promotions complex or cyclosome (APC/C) and thereby 
prevents the degradation of its key substrates including cyclin B and securin (Foley and 
Kapoor 2013; Musacchio and Salmon 2007). Thus, activation of the SAC in the early 
phases of mitosis prevents premature sister chromatic separation and exit from mitosis. 
 
1.3. Genome instability and tumor evolution 
A major hallmark of human cancer is the presence of profound alterations of genome. 
Different forms of genome instability can be distinguished: 
1. Accumulations of point mutations, which are due to defects in mismatch or 
nucleotide excision repair (Wood 1997). A particular form of this phenotype 
in colorectal cancer (CRC) is known as microsatellite instability (MIN/MSI), 
where defects in mismatch repair genes account for instabilities of 
microsatellite sequences (Lengauer et al. 1997). 
2. Accumulation of segmental or structural chromosome aberrations, which can 
be due to DNA repair or replication defects (Feuk et al. 2006). This form of 





instability is termed as segmental or structural chromosome instability (S-CIN) 
(Geigl et al. 2008). 
3. Accumulation of numerical aneuploidy, which arises upon whole chromosome 
missegregation during mitosis. This form of instability is called whole 
chromosome instability (W-CIN) (Geigl et al. 2008). In fact, chromosomally 
stable cells show less than 1% of cell division missegregation events, whereas 
in W-CIN cells this rate is increased to 20%-50% (Lengauer et al. 1997; 
Thompson and Compton 2008). 
 
1.3.1. Causes of W-CIN 
Different causes responsible for the induction of W-CIN have been discussed 
(Bastians 2015; Thompson et al. 2010). For instance, malfunction of the spindle 
assembly checkpoint (Musacchio and Salmon 2007), the presence of supernumerary 
centrosomes (Pihan et al. 1998) or defects in the chromatid cohesion (Barber et al. 
2008) can account for the mitotic chromosome missegregation and W-CIN. A recent 
study revealed that DNA replication stress can also cause W-CIN (Burrell et al. 2013). 
In fact, while induction of replication stress induced aneuploidy, a lleviating 
replication stress in cancer cells reduced the frequency of chromosome 
missegregation (Burrell et al. 2013).  
A major source for W-CIN appears to be the generation of erroneous 
microtubule-kinetochore interactions (Foley and Kapoor 2013). Three types of 
erroneous attachments can occur (1) Monotelic attachments, where only one of the 
sister kinetochores attaches to microtubules. (2) Syntelic attachments, where both 
sister kinetochores attach to the microtubules from the same spindle pole. (3) 
Merotelic attachments, where one kinetochore attaches to microtubules from both 
spindle poles (Figure 1-2) (Tanaka and Hirota 2009, 2016). Monotelic and syntelic 
attachments can directly or indirectly be sensed by the SAC, which detects the lack of 
microtubule attachment to the kinetochores or the lack of proper tension generated 
between the two kinetochores (Tanaka and Hirota 2009). The SAC delays anaphase 
onset until the errors are corrected. However, merotelic attachments, cannot be sensed 
by the SAC and thus, can lead to missegregation of chromosomes (Gregan et al. 
2011). It is thought that merotelic attachments are a leading cause for W-CIN and are 





associated with the generation of lagging chromosomes during anaphase (Figure 1-2b) 
(Gregan et al. 2011; Nicholson and Cimini 2013). 
 
 
Figure 1-2 Classification of kinetochore-microtubule attachments 
(a) Four types of kinetochore-microtubule attachments are described. (i) Bipolar 
(amphitelic) attachments describe kinetochores attached to microtubules emanating 
from opposite spindle poles. (ii) Monotelic attachments involve kinetochores attached 
to the microtubules emanating from the same pole. (iii) Syntelic attachments are 
defined as kinetochores attached to the microtubules emanating from the same spindle 
pole. (iv) Merotelic attachments are conditions where a single kinetochore is attached 
to microtubules from both spindle poles. (b) Merotelic attachments can lead to 
lagging chromosomes during anaphase. (i) The lagging chromosomes can segregate to 
the wrong side resulting in whole chromosome aneuploidy. (ii) Lagging chromosomes 
can be entrapped in micronuclei and maybe subsequently damaged by the recapture of 
micronuclei, which can lead to structural aneuploidy. (Figure is modified from 
Tanaka and Hirota, 2016, p. 67) 
 





Interestingly, the presence of supernumerary centrosomes can lead to the formation of 
transient multipolar spindle intermediates that support the formation of merotelic 
kinetochore attachments and thereby, causes chromosome missegregations and 
W-CIN. 
Recently, our lab established that increased microtubule plus-end assembly rates 
within mitotic spindles can contribute to CIN. By analyzing the plus-end assembly 
rates during mitosis in MIN/MSI and CIN colorectal cancer (CRC) cell lines, it was 
revealed that elevated MT growth rates are present only in CIN cells. Moreover, 
restoration of proper microtubule assembly rates in CIN cells by chemical suppression 
of microtubule dynamics (by treatment with low-doses of Taxol) or by partial 
repression of the microtubule polymerase ch-TOG/CKAP5 was sufficient to suppress 
W-CIN. Vice versa, by genetic means (e.g. by overexpression of Aurora-A or by the 
loss of CHK2) or by treatment with low-doses of nocodazole, microtubule plus-end 
assembly rates were increased, thereby inducing the generation of lagging 
chromosomes, chromosome missegregation and CIN. These findings revealed that 
abnormally increased microtubule growth rates during mitosis can act as a trigger for 
the induction of CIN. Importantly, by the use of Taxol treatment or by repression of 
ch-TOG/CKAP5 CIN can be efficiently suppressed in otherwise chromosomally 
instable cancer cells (Ertych et al. 2014). 
 
1.3.2. Consequences of CIN 
CIN is a key characteristic of almost all solid cancers (Ohyashiki et al. 2017). It is 
thought that CIN can drive tumor cell evolution by altering gene expression that may 
facilitate rapid cell adaptation (McGranahan et al. 2012). In this way, CIN can 
contribute to genetic heterogeneity in cancer and thereby might drive therapy 
resistance, a major problem in the clinic (Chen et al. 2012; Gerlinger et al. 2014; 
Turner and Reis-Filho 2012). The relationship between cancer prognosis and CIN has 
been explored across multiple types of cancers.  
In non-small-cell lung cancer (NSLCL), several independent studies found that CIN 
was a poor prognosis factor. It was independent of conventional risk factors such as 
sex, age, and tumor stage in variate analysis (Choi et al. 2009; Nakamura et al. 2003; 
Yoo et al. 2010). In breast cancers, however, CIN is a prognostic factor that is 





dependent on the estrogen receptor (ER) state. In ER-positive breast cancers, CIN is 
associated with tumor progression and unfavorable prognosis (Smid et al. 2011). 
While in ER-negative breast cancer, CIN is associated with an improved prognosis 
(Birkbak et al. 2011; Roylance et al. 2011). In colorectal cancer (CRC) CIN 
correlated with a worse prognosis regarding overall survival or progress- free survival 
compared to the non-CIN CRC (Walther et al. 2008). Studies in other cancers such as 
oral, ovarian, synovial, and endometrial cancers, together with diffuse large B-cell 
lymphomas have also demonstrated that CIN is associated with poor prognosis 
(Bakhoum et al. 2011; Murayama-Hosokawa et al. 2010; Nakagawa et al. 2006; Sato 
et al. 2010). Hence, these studies have established that CIN is an important prognosis 
factor in a wide range of cancer types.  
 
1.3.3. Cancer genome evolution 
The basic evolution principles of Darwin evolution that the differential fitness 
variation is heritable can be applied in the context of cancer evolution (Nowell 1976).  
When a tumor is detected, it has undergone many generations of cell division, and 
cells have stochastically acquired somatic mutations in each generation (Gerlinger et 
al. 2014; Rosenthal et al. 2017). Among these mutations, a small subset of mutations 
called driver events may show evolutionary advantage that allows the cells to 
outcompete others (Rosenthal et al. 2017). Also, the clonal selection and evolution of 
the cells may lead to outgrowth of subclones that lead to branched evolutionary 
phylogenies (Gerlinger et al. 2012; Gundem et al. 2015). 
The majority of established driver events are clonal, which indicates that the clonal 
driver events may occur in the early stage of tumor evolution (McGranahan et al. 
2015; McGranahan and Swanton 2015). Whereas subclonal driver events that have 
been identified across numerous cancers are believed to play a role in tumor 
maintenance and progression (Yates et al. 2015). Subclonal populations of cancer 
cells induce a heterogeneous environment within the tumor. However, each subclone 
is not an isolated entity (Rosenthal et al. 2017). Studies have also revealed that 
genetically distinct subclones interact with each other to some extent during tumor 
evolution and this interaction may be competitive or cooperative (Marusyk et al. 
2014). For vital resources such as nutrients, oxygen, or space, one subclone may 





outcompete another (Marusyk and Polyak 2010). To many aspects, clonal cooperation 
contributes to tumor growth and progression (Neelakantan et al. 2015; Polyak and 
Marusyk 2014). For example, through endocrine signaling networks, low-frequency 
clones may promote resistance to treatment or support the growth of dominant clones 
(Acharyya et al. 2012; Chung et al. 2013; Hobor et al. 2014). Clonal interference can 
also result in tumor collapse. When a subclone that outcompetes the subclone that 
drives tumor growth is dependent on the current microenvironment, a change in the 
tumor environment may lead to tumor collapse (Marusyk et al. 2014).   
In sum, tumors represent a complex dynamic ecological system, in which 
heterogeneity can promote tumor development and progression but not only a 
substrate of evolution.  
 
1.3.4. CIN and responses to anti-cancer treatment 
Assuming that all cancer cells are sensitive to a given treatment to the same extent, 
any therapy that kills the cancer cells faster than they divide would eventually result 
in a cure of the disease. Unfortunately, the tumor heterogeneity prevents this from 
happening in most cases. Drug resistance is a severe problem for cancer treatment. 
Numerous examples reveal that tumor heterogeneity can drive drug resistance. 
Epidermal growth factor receptor (EGFR) gene heterogeneity within non-small-cell 
lung cancers results in a reduced gefitinib response (Taniguchi et al. 2008). In CRCs, 
the clonal evolution drives anti-EGFR treatment resistance (Siravegna et al. 2015). To 
assess the association between CIN and drug response in CRC, Lee and colleagues 
treated CIN and non-CIN cell lines of CRC individually with a library of kinase 
inhibitors. They found that CIN cell lines showed significantly increased multidrug 
resistance compared to non-CIN cells, which was independent of somatic mutation 
status. Tetraploid isogenic cells showed generally higher resistance compared to their 
diploid counterparts (Lee et al. 2011).       
Taken together, these studies indicate that tumor heterogeneity is related with drug 
resistance and poor clinical outcome in diversity cancers. 
 





1.4. Colorectal cancer 
Colorectal cancer (CRC) is a premier model for studying CIN. It is the third most 
diagnosed cancer in worldwide (Rao et al. 2016). MIN/MSI and CIN are two main 
distinct patterns of genomic instability in CRC (Lengauer et al. 1998). 80%-90% of 
CRC cases are characterized by CIN and this is thought to contribute to progression 
and recurrence of the disease (Rao et al. 2016). Due to its high incidence, the 
investigation of CIN in CRCs has a high clinical relevance. CRCs often show 
nonmucinous histology, moderate differentiation and less tumor- infiltrating 
lymphocytes (Silver et al. 2012; Sinicrope et al. 2006). Most CRCs exhibit APC, 
KRAS, and TP53 mutation and these genetic alterations are associated with CIN 
(Rowan et al. 2005). Moreover, CIN is clearly associated with bad prognosis and 
reduced the patient survival in CRC (Watanabe et al. 2012).   
The treatment of CRCs is based on number, size, localization and progression of the 
tumor, presence or absence of biochemical markers and the health condition of the 
patients. The treatment strategies for CRCs include surgical resection, chemotherapy, 
and monoclonal antibodies against EGFR and vascular endothelial growth factor 
(VEGF) in KRAS wild-type tumors combined with traditional chemotherapy. Most 
patients with metastatic CRC disease are treated with chemotherapy. The first line of 
chemotherapy with fluoropyrimidines (5-FU or Capecitabine) combined with 
Leucovorin, and other cytotoxic agents, such as Irinotecan (5-FU/LV/Irinotecan 
(FOFIRI)), or Oxaliplatin (5-FU/Leucovorin/oxaliplatin (FOLFOX)) and 
(Capecitabine/Leucovorin/Oxaliplatin (CAPOX)). Leucovorin can increase the 
reaction rate of fluoropyrimidines. When tumors relapse, and the patients have good 
tolerance a second line chemotherapy is frequently used. When patients are refractory 
to Irinotecan, the Oxaliplatin-containing regimens FOLFOX or CAPOX can be used. 
When refractory to Oxaliplatin, Irinotecan monotherapy or FOLFIRI can be utilized 
(Benson et al. 2017). 
 
1.5. Scope of the study 
This thesis project aimed to address whether ongoing chromosome missegregation 
constituting a W-CIN phenotype affects therapy response in CRC cells in vitro. For 
this, I used chromosomally instable CRC cells, in which the W-CIN phenotype and 





chromosome missegregation could be specifically suppressed. On the other hand, I 
also induced the W-CIN phenotype in chromosomally stable CRC cells. CRC cells 
with or without W-CIN were treated with clinical relevant chemotherapeutic drugs 
including 5-FU, Oxaliplatin, Irinotecan, Cisplatin, and Adriamycin. The drug 
responses were assessed by colony formation assays and FACS analysis. The goal of 
the project was to investigate whether W-CIN, perpetual chromosome missegregation 































2. Materials and Methods 
 
2.1. Materials 
All the working materials including cell culture dishes, pipette tips and reaction tubes 




Equipment used to assist this study is listed in Table 2-1.  
Table 2-1 Equipment 
Equipment Model Company 
CO2 Incubator HERAcell 240 CO2 
Incubator 
Thermo Fisher Scientific, 
Karlsruhe, Germany 




Power supply EV231 Peqlab, Erlangen, Germany 
Flow Cytometer BD FACSCanto©Ⅱ Becton Dickinson, San Jose, 
CA, USA 
Electroporation Device GenePulser Xcell© BioRad Laboratories, 
München, Germany 
Magnetic Mixer IKAMAG© RCT IKA Laboratories, München, 
Germany 
Microscope Zeiss Axio Imager Z1 Zeiss, Göttingen, Germany 
Microscope Camera 
Adaptor 
A3474-07 Hamamatsu Photonics, 
Hamamatsu, Japan 
Pipettes Pipetman© Gilson International, 
LimburgOffheim, Germany 
Pipettor Pipetboy acu Intergra Biosciences, 
Fernwald, Germany 





Equipment Model Company 
Sterile Workbench HERAsafeM Thermo Fisher Scientific, 
Karlsruhe, Germany 




Biofuge fresco Thermo Fisher Scientific, 
Karlsruhe 
Vortex Mixer VORTEX-GENIE©2 Scientific Industries Inc., 
Bohemia, NY, USA 
Quato IntelliScan  Quato IntelliScan 1600 Quatographic Technology, 




The software used in the study is listed in Table 2-2 
Table 2-2 Software 
Software  Company 
Hokawo Laucher Hamamatsu Photonics, Hamamatsu, 
Japan 
ImageJ NIH Image, Bethesda, MD, USA 
BD FACSDivaTM Becton Dickinson, San Jose, CA, USA 
Prism 6 Graphpad, La Jolla, CA, USA 
 
2.1.3. Chemotherapeutic drugs and inhibitors 
All chemotherapeutic drugs and inhibitors used in this study were purchased from 
Sigma-Aldrich (Taufkirchen, Germany), VWR international (West Chester, PA, 
USA), Th. Geyer (Höxter, Germany), Santa Cruz (Dallas, TX, USA), Calbiochem (La 
Jolla, CA, USA). 
Chemotherapeutic drugs and inhibitors used in this study and the ir respective working 
concentrations and effects are listed in Table 2-3.  




















Adriamycin (Myers et 
al. 1977)  
5, 10, 15, 20, 
30, 50, 400, 
600 nM 
Intercalates 




H2O 500 μM Th. Geyer, 
Höxter, 
Germany 
Oxaliplatin  (Arango 
et al. 2004) 
0.1, 0.2, 0.4, 













0.2, 04, 0.8, 







PBS 5 mM Santa Cruz, 
Dallas, TX, 
USA 
5-FU (Longley et al. 
2003) 
0.2, 0.5, 1, 2, 







into RNA and  
DNA 
DMSO 50 mM Sigma-Aldrich 
Taufkirchen, 
Germany 

















Irinotecan (Hurwitz et  
al. 2004) 
0.05, 0.1, 0.2, 









(DME) (Gartner et al. 
2005) 
2 μM Inhibition 
EG5-kinesin 
DMSO 10 mM Calbiochem, 




1μg/ml Inhibition of 
translation 
DMSO 1 mg/ml Sigma-Aldrich 
Taufkirchen, 
Germany 
Taxol (Sch iff et al. 
1979) 
0.5 nM Stabilization 
of 
microtubules 




et al. 1978) 
1, 2 μg/ml Inhibition 
DNA 
polymerase  




et al. 2013) 
0.5 μM Inhibition 
MPS1 





2.1.4. Human cell lines 
Human cell lines used for this study are listed in Table 2-4. The table also provides 










Table 2-4 Human cell lines 























(Ertych et al. 
2014) 




(Ertych et al. 
2014) 
 
Colorectal cancer HCT116 and SW620 cell lines were purchased from the American 
Type Culture Collection (ATCC; Manassas, VA, USA). HCT116-CHK2-/- cells were 
kindly provided by Prof. Bert Vogelstein (John Hopkins University, Baltimore, 
Maryland, USA).  
 
2.2.  Methods 
 
2.2.1. Cultivation of human cell lines 
Human cell lines were cultured in RPMI 1640 medium (Sigma-Aldrich, Taufkirchen, 
Germany) supplemented with 10% (v/v) Fetal Calf Serum (FCS) (GE Healthcare, 
Chalfont St. Giles, Great Britain), 100 μg/ml streptomycin and 100 U/ml penicillin 
(Sigma-Aldrich, Taufkirchen, Germany) at 37°C with 5% CO2 in a humidified 
incubator. Cells were splitted every 2-3 days to enable enough space and sufficient 
nutrient supply for proliferation. To do this, cells were washed with 10 ml PBS once 
and detached by 1 ml trypsin-EDTA (Sigma-Aldrich, Taufkirchen, Germany) 
treatment. A defined dilution of cell suspension was transferred in to a new cell 
culture dish containing RPMI 1640 medium. Stable cell lines expressing shRNA that 





targeting ch-TOG/CKAP5 and the control scrambled shRNAs were growing in the 
presence of 1 μg/ml puromycin. HCT116-CHK2-/- cells were growing in the presence 
of 300 μg/ml G418. 
 
Cells were stored in liquid nitrogen for long time storage. For this, cells were 
harvested and centrifuged at 1,000 rpm, then resuspended in 400 μl freezing med ium, 
which containing 70%(v/v) RPMI 1640, 20%(v/v) FCS and 10% (v/v) DMSO. The 
cell suspensions were slowly cooling down to -80°C by using a cryo freezing box 
filled with 2-propanol (VWR international, West Chester, PA, USA) and transferred 
to the vapor phase of liquid nitrogen after 24 h. 
 
2.2.2. Generation of single cell clones in the presence of Aphidicolin or 
MPS1-IN-3. 
1,000 HCT116 cells were seeded into 10 cm cell culture dish 24 h before the 
treatment. The cells were treated with RPMI 1640 medium containing 1ng/ml or 2 
ng/ml Aphidicolin or 0.5 μM MPS1-IN-3 or DMSO. RPMI 1640 medium containing 
drug was changed every 2-3 days. After 7 days small colonies were transferred into a 
24-well plate, and further cultivated in the presence of the drug. After growing for 30 
generations, single cell clones were analyzed. 
 
2.2.3. Karyotype analysis by metaphase chromosome counting 
Cells were treated with 2 uM DME for 4h to arrest in mitosis. Afterwards the cells 
were harvested in 15 ml Falcon tube and centrifuged at 1,000 rpm. To swell the cells, 
the cell pellets were resuspended in 2 ml hypotonic solution (40%(v/v) RPMI 1640 
medium in aqua dest) and incubated at room temperature (RT) for 20 min. 
Subsequently, the swelled cells were fixed with 1 ml ice-cold Carnoy’s fixdative 
(75%(v/v) methanol, 25%(v/v) glacial acetic acid) and centrifuged at 2,000 rpm for 5 
min. The fixation step was repeated 3 times. Then the cells were directly processed or 
stored at -20°C until further usage. Cells were resuspended in 100 - 500 μl 100% 
glacial acetic acid and dropped onto a pre-cooled, wet objective slide from a vertical 
height of about 30 cm. The objective slides with cell drops were incubated at 42°C in 
a wet chamber for 5 min. Afterwards the slides were dried at RT. After the objective 





slides had been thoroughly dried, they were stained with 8% (v/v) Giemsa staining 
solution (Merck, Darmstadt, Germany) for 25 min. Objective slides were then washed 
and dried at RT. After thoroughly dried, the objective slides were embedded into 
Euparal (Carl Roth, Karlsruhe, Germany). The stained objective slides were analyzed 
by a Zeiss Axioscope FS microscope (Zeiss, Oberkochen, Germany) equipped with a 
Hamamatsu C4742-95 camera and the Hokawo Launcher 2.1 software (Hamamatsu 
Photonics, Hamatsu, Japan). 
 
2.2.4. Flow cytometry 
A BD FACS Canto II (Becton Dickinson, San Jose, CA, USA) was used to perform 
Fluorescence Activated Cell Sorting (FACS) analysis. BD FACS DivaTM (Becton 
Dickinson, San Jose, CA, USA) software was used to analyze the data. Cells were 
harvested in 15 ml Falcon tube and centrifuged 5 min at 1,000 rpm. Afterwards the 
cells were resuspended in 200 μl PBS. After fixing in 1 ml 70% (v/v) ice-cold ethanol, 
which was added dropwise while the suspension was continuously vortexing, the cells 
were subsequently stored at 4°C overnight. DNA intercalating dye propidium iodide 
(PI) (Sigma-Aldrich, Taufkirchen, Germany) was used to determine the DNA content. 
Fixed cells were centrifuged at 2,000 rpm for 5 min, the cell pellet was washed with 1 
ml PBS once, then resuspended in 100 ul 1μg/ml DNA free RNase A (Applichem, 
Darmstadt, Germany) and incubated at RT for 15 min. After adding 10 μ l 50 μg/ml PI 
the cells were analyzed.  
 
2.2.5. Colony formation assay  
3,000 cells were seeded in 6-well plate 24 h before the treatment. The cells were 
treated with different concentrations of Oxaliplatin (VWR International, West Chester, 
PA, USA), Adriamycin (Th. Geyer, Höxter, Germany), 5-FU (Sigma-Aldrich 
Taufkirchen, Germany), Irinotecan (VWR International, West Chester, PA, USA), 
Cisplatin (Santa Cruz, Dallas, TX, USA). Cells were incubated at 37°C and 5% CO2 
for 10 days. The RPMI1640 medium containing the drugs was changed every 2-3 
days. The growing colonies were fixed with 70% (v/v) ethanol and stained with 
crystal violet solution (0,1%(w/v) Crystal violet, 20% (v/v) ethanol in H2O). The 
growth area was scanned using a Quato IntelliScan 1600 (Q uatographic Technology, 





Schleswig - Holstein, Germany) and colony area was determined by using 
ColonyArea plugin of ImageJ (NIH Image, Bethesda, MD, USA) (Guzman et al. 
2014). 
 
2.2.6. Statistical analysis 
All data are shown as mean ± standard error of the mean (sem.). One tailed Student’s 































3. Results  
 
3.1. Responses towards platinum drugs in cells exhibiting CIN and 
after suppression of CIN. 
 
3.1.1. Suppression of CIN in HCT116-CHK2-/- but not in SW620 by treatment 
with low-dose of Taxol results in increased sensitivity towards Oxaliplatin 
treatment. 
 
Figure 3-1 Schematic overview of single cell clones in the presence or absence of 
low-dose of Taxol. 
Two independent single cell clones derived from HCT116-CHK2-/- or SW620 were 
treated with 0.5 nM Taxol for 30 generations. These cell clones were cultured either 
in the presence of 0.5 nM Taxol (+Taxol) or absence of Taxol (-Taxol) for another 30 
generations. After 60 generations, these cell clones were treated with different 
chemotherapeutic drugs for 10 days for colony formation assay. The cells 
continuously cultured with 0.5 nM Taxol were also treated with different drugs in the 
absence of 0.5 nM Taxol during the assay of 10 days (+/-Taxol). 
 





Treatment with low-dose of Taxol restores proper mitotic microtubule assembly rates 
and suppresses CIN in chromosomally unstable colorectal cancer cells (Ertych et al. 
2014). I investigated whether suppression of CIN impacted on drug response towards 
chemotherapeutic drugs. For this, I used two independent single cell clones of 
HCT116-CHK2-/- and SW620 cells, both of which exhibited increased microtubule 
plus-end assembly rates and CIN, which were treated with Taxol for 30 generations 
thereby suppressing CIN. Single cell clones generated in the presence of Taxol were 
used for the subsequent colony formation assays. Each cell clone was either treated 
with Taxol for another 30 generations (suppressed CIN) or left untreated for a nother 
30 generations (re- induced CIN). I treated these cell clones with increasing 
concentrations of Oxaliplatin in the presence of Taxol (suppressed CIN) or in the 
absence of Taxol (CIN) (Figure 3-1).  
 
 
Figure 3-2 Quantification of the area of the cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentration of Oxaliplatin in the presence 
or absence of low-dose of Taxol.  
(a) Cells of HCT116-CHK2-/- cell clone 1 were treated with increasing concentrations 
of Oxaliplatin in the presence or absence of 0.5 nM Taxol and the area of the cell 





colonies was determined after ten days. (b) Cells of HCT116-CHK2-/- cell clone 2 
were treated with increasing concentrations of Oxaliplatin in the presence or absence 
of 0.5 nM Taxol and the area of the cell colonies was determined after ten days. (c) 
Cells of SW620 cell clone 1 were treated with increasing concentrations of 
Oxaliplatin in the presence or absence of 0.5 nM Taxol and the area of the cell 
colonies was determined after ten days. (d) Cells of SW620 cell clone 2 were treated 
with increasing concentrations of Oxaliplatin in the presence or absence of 0.5 nM 
Taxol and the area of the cell colonies was determined after ten days. For the colony 
formation assays, 3,000 cells were seeded 24 h before treatment, and five different 
concentrations of oxaliplatin were used as indicated. After ten days of the area of the 
cell colonies covered by the cells was determined. The areas of the cell colonies were 
normalized to control treated cells and represented as bar graphs (mean ± sem., t-test, 
n=3 independent experiments, ns = not significant). 
 
Colony formation assays in the continuous presence of Oxaliplatin revealed that 
HCT116-CHK2-/- cells that grown in the absence of Taxol were more resistant 
towards Oxaliplatin compared to the same clone grew in the presence of low-does 
Taxol (Figure 3-2a and 3-2b). In HCT116-CHK2-/-  single clone 1 cells, the area of 
the cell colonies in the absence of Taxol was 1.41-fold greater than the cells in the 
presence of Taxol when treated with 0.2 μM Oxaliplatin, and was 1.97-fold greater 
when treated with 0.4 μM Oxaliplatin (Figure 3-2a). In the second single cell clone of 
HCT116-CHK2-/- cells, the area of the cell colonies in the absence of Taxol was 
1.44-fold greater than the cells in the presence of Taxol when treated with 0.4 μM 
Oxaliplatin, and was 1.71-fold greater when treated with 0.8 μM Oxaliplatin (Figure 
3-2b). However, no significant differences in drug sensitivity were detectable in two 
independent cell clones of SW620 cells that grown in the presence or absence of 
Taxol (Figure 3-2c and 3-2d).  
 





3.1.2. Short-term re-induction of chromosome missegregation mediated by 
short-term removal of Taxol results in decreased sensitivity towards 
Oxaliplatin in HCT116-CHK2-/- cells, but not in SW620 cells.  
Long-time (30 days) removal Taxol can re- induce CIN and aneuploidy in the same 
clone generated in the presence of low-dose of Taxol (Ertych et al. 2014). To 
investigate whether short-term removal of Taxol and thus, acute chromosome 
missegregation without significant alterations of the karyotype impacted on the drug 
response, I used two cell clones for HCT116-CHK2-/- and two cell clones for SW620 
cells that were continuously grown in the presence of Taxol to suppress CIN. These 
cells were then treated with increasing concentrations of Oxaliplatin in the presence 
or absence of Taxol during the colony formation assay for ten days only (Figure 3-1). 
 
Figure 3-3 Quantification of the area of the cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentration of Oxaliplatin in the presence 
or short time absence of low-dose of Taxol. 
 (a) HCT116-CHK2-/- cells of Taxol-treated clone 1 were treated with increasing 
concentrations of Oxaliplatin in the presence or absence of 0.5 nM Taxol during the 
assay, and the area of the cell colonies was determined after ten days. (b) 
HCT116-CHK2-/- cells of Taxol treated clone 2 were treated with increasing 





concentrations of Oxaliplatin in the presence or absence of 0.5 nM Taxol during the 
assay, and the area of the cell colonies was determined after ten days. (c) SW620 cells 
of Taxol treated clone 1 were treated with increasing concentrations of Oxaliplatin in 
the presence or absence of 0.5 nM Taxol during the assay, and the area of the cell 
colonies was determined after ten days. (d) SW620 cells of Taxol treated clone 2 were 
treated with increasing concentrations of Oxaliplatin in the presence or absence of 0.5 
nM Taxol, and the area of the cell colonies was determined after ten days. The areas 
of the cell colonies were normalized to control treated cells and represented as bar 
graphs (mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 
These analyses revealed that HCT116-CHK2-/- cells that grew in the absence of Taxol 
during the assay were more resistant towards Oxaliplatin compared to the same cells 
cultured in the presence of Taxol (Figure 3-3a and 3-3b). In clone 1 of 
HCT116-CHK2-/- cells, the area of the cell colonies in the absence of Taxol during the 
assay was 1.18-fold greater than the cells in the presence of the Taxol when treated 
with 0.2 μM Oxaliplatin, and was 1.49-fold greater when treated with 0.4 μM 
Oxaliplatin (Figure 3-3a). Whereas the area of the cell colonies in the absence of 
Taxol was 1.24-fold greater than the cells in the presence of Taxol when treated with 
0.2 μM Oxaliplatin, 1.65-fold greater when treated with 0.4 μM Oxaliplatin, and 
2.91-fold greater when treated with 0.8 μM Oxaliplatin in clone 2 of 
HCT116-CHK2-/- cells (Figure 3-3b). However, no significant response differences 
were found in two independent clones of SW620 cells that were growing in the 
presence or short-term absence of Taxol (Figure 3-3 c and 3-3d).   
 
 
3.1.3. Suppression of CIN by stable knockdown of ch-TOG/CKAP5 in 
HCT116-CHK2-/- and SW620 results in increased sensitivity towards 
Oxaliplatin treatment.  
Partial stable knockdown of ch-TOG/CKAP5 restores proper mitotic plus-end 
microtubule assembly rates and suppresses CIN in chromosomally unstable colorectal 
cancer cells (Ertych et al. 2014). I used two independent stable ch-TOG/CKAP5 
knockdown single cell clones of HCT116-CHK2-/- and SW620 cells to investigate 





whether suppression CIN affects drug response towards Oxaliplatin independently of 
Taxol treatment. Compared with the control cell clones, ch-TOG/CKAP5 knockdown 
cells were more sensitive towards Oxaliplatin treatment in HCT-CHK2-/- cells (Figure 
3-4a). In HCT116-CHK2-/- cells, the mean value of the area of the control cell 
colonies was 1.25-fold greater than ch-TOG/CKAP5 knockdown cells when treated 
with 0.1 μM Oxaliplatin, 1.85-fold greater when treated with 0.2 μM Oxaliplatin, and 
5.38-fold greater when treated with treated with 0.4 μM Oxaliplatin (Figure 3-4a). 
SW620-shch-TOG clones showed increased sensitivity towards Oxaliplatin (0.1 and 
0.2 μM) as well, albeit at a lesser extent (Figure 3-4b).  
 
Figure 3-4 Quantification of area of the cell colonies treated with different 
concentration of Oxaliplatin in HCT116-CHK2-/--shch-TOG and 
SW620-shch-TOG cells. 
(a) Two independent shRNA control single cell clones and two different shch-TOG 
single cell clones derived from HCT116-CHK2-/- were treated with increasing 
concentrations of Oxaliplatin, and the area of the cell colonies was determined after 





ten days. (b) Two independent shRNA control single cell clones and two different 
shch-TOG single cell clones derived from SW620 were treated with increasing 
concentrations of Oxaliplatin, and the area of the cell colonies was determined after 
ten days. The areas of the cell colonies were normalized to control scrambled cells 




3.1.4. Suppression of CIN in HCT116-CHK2-/- cells by low-dose of Taxol does 
not result in acute response differences towards Oxaliplatin. 
To further investigate the acute cellular response towards higher concentrations of 
Oxaliplatin in HCT116-CHK2-/- cells after CIN suppression, I used FACS analyses to 
analyze the acute cell response in the presence or absence of low-dose of Taxol 
treated with increasing concentrations (1 μM, 4 μm and 8 μM) of Oxaliplatin in cells 
of HCT116-CHK2-/- clone 1. These cells were cultured in the presence of low-dose 
Taxol (+Taxol), only in the absence of Taxol for 30 days (-Taxol), or absence of 
Taxol only during the Oxaliplatin treatment (+/-Taxol). After 48 h of treatment, the 
proportion of cells with a Sub-G1 DNA content, which represents apoptotic cells 
(Kajstura et al. 2007), was determined by FACS.  
These analyses overall revealed no drug response differences torwards Oxaliplatin 
between CIN and after suppression CIN by Taxol. Only after treatment with 8 μM 
Oxaliplatin, cells that were grown in the absence of Taxol showed more apoptotic 
cells in response of the drug treatment (Figure 3-5). 






Figure 3-5 Analyses of the acute cellular response towards different 
concentrations of Oxaliplatin treatment in cells of HCT116-CHK2-/- Clone 1 in 
the presence or absence of Taxol. 
(a) DNA content profiles of HCT116-CHK2-/- in the presence or absence of low-dose 
Taxol after 48 h of Oxaliplatin treatment. (b) The proportion of cells with a Sub-G1 
DNA content after 48 h different concentrations of Oxaliplatin treatment was 














































3.1.5. Suppression of CIN treated by low-dose of Taxol does not result in 
response differences towards Cisplatin neither in HCT116-CHK2-/- nor in 
SW620 cells.         
Cisplatin is the first generation of platinum compounds. Its cytotoxic mode of action 
is mediated by its interaction with DNA to form DNA adducts, which is similar to 
Oxaliplatin (Siddik 2003). I used Cisplatin to test whether it had a similar effect as 
Oxaliplatin on cell growth after CIN suppression. On a cell growth after CIN 
suppression, however, unlike Oxaliplatin, colony formation assays revealed that no 
differences in drug sensitivity in the presence or absence of Taxol in 
HCT116-CHK2-/- cells (Figure 3-6a and 3-6b). Similar results were observed in two 
independent cell clones of SW620 cells (Figure 3-6c and 3-6d). 
 
 
Figure 3-6 Quantification of the area of the cell colonies of HCT116-CHK2-/- and 
SW620 cells after treatment with different concentration of Cisplatin in the 
presence or absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- cell clone 1 were treated with increasing concentrations 
of Cisplatin in the presence or absence of 0.5 nM Taxol and the area of the cell 
colonies was determined after ten days. (b) Cells of HCT116-CHK2-/- cell clone 2 





were treated with increasing concentrations of Cisplatin in the presence or absence of 
0.5 nM Taxol and the area of the cell colonies was determined after ten days. (c) Cells 
of SW620 cell clone 1 were treated with increasing concentrations of Cisplatin in the 
presence or absence of 0.5 nM Taxol and the area of the cell colonies was determined 
after ten days. (d) Cells of SW620 cell clone 2 were treated with increasing 
concentrations of Cisplatin in the presence or absence of 0.5 nM Taxol and the area of 
the cell colonies was determined after ten days. The areas of the cell colonies were 
normalized to control treated cells and represented as bar graphs (mean ± sem., t-test, 
n=3 independent experiments, ns = not significant). 
 
3.1.6. Short-term re-induction of chromosome missegregation does not result in 
response differences towards Cisplatin in HCT116-CHK2-/- and SW620 
cells. 
 
Figure 3-7 Quantification of the area of cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentration of Cisplatin in the presence or 
short-term absence of low-dose of Taxol. 
 (a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of Cisplatin in the presence or absence of 0.5 nM Taxol during the 





assay, and the area of the cell colonies was determined after ten days. (b) Cells of 
HCT116-CHK2-/- single cell clone 2 were treated with increasing concentrations of 
Cisplatin in the presence or absence of 0.5 nM Taxol during the assay, and the area of 
the cell colonies was determined after ten days. (c) Cells of SW620 single cell clone 1 
were treated with increasing concentrations of Cisplatin in the presence or absence of 
0.5 nM Taxol during the assay, and the area of the cell colonies was determined after 
ten days. (d) Cells of SW620 cell single cell clone 2 were treated with increasing 
concentrations of Cisplatin in the presence or absence of 0.5 nM Taxol during the 
assay, and the area of the cell colonies was determined after ten days. The areas of the 
cell colonies were normalized to control treated cells and represented as bar graphs 
(mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 
Removal of Taxol during the colony formation assay was also used during Cisplatin 
treatment. However, no drug sensitivity differences towards Cisplatin were found in 
two independent cell clones of HCT116-CHK2-/- cells that grown in the absence of 
Taxol during the colony formation assay (Figure 3-7a and 3-7b). Similar results were 
obtained for two independent clones of SW620 cells that were grown in the presence 
or short-term absence of Taxol (Figure 3-7c and 3-7d). 
 
3.1.7. Taxol treatment does not affect drug response towards Oxaliplatin or 
Cisplatin per se. 
 
Figure 3-8 Quantification of the area of cell colonies of cell populations of 
HCT116 treated with different concentrations of Oxaliplatin or Cisplatin. 
(a) HCT116 cells were treated with increasing concentrations of Oxaliplatin in the 
presence of 0.5 nM Taxol or DMSO, and the area of the cell colonies was determined 





after ten days. (b) HCT116 cells were treated with increasing concentrations of 
Cisplatin in the presence of 0.5 nM Taxol or DMSO, and the area of the cell colonies 
was determined after ten days. The areas of the cell colonies were normalized to 
control treated cells and represented as bar graphs (mean ± sem., t-test, n=4 
independent experiments, ns = not significant). 
 
To investigate whether low-dose treatment of Taxol itself affects drug response, I 
used chromosomally stable HCT116 cells and treated them with Oxaliplatin or 
Cisplatin in the presence or absence of Taxol. After ten days of treatment, no drug 
response differences were detectable (Figure 3-8). Thus, low-dose of Taxol does not 
affect drug response towards Oxaliplatin or Cisplatin per se. 
 
 
3.1.8. Suppression of CIN by knockdown of ch-TOG/CKAP5 results in 
decreased sensitivity in HCT116-CHK2-/-, but increased sensitivity in 
SW620 towards Cisplatin treatment.  
The ch-TOG/CKAP5 stable knockdown cells of HCT116-CHK2-/- and SW620 
showed increased sensitivity towards Oxaliplatin treatment (Figure 3-4), to test 
whether these cells also exhibit increased sensitivity towards Cisplatin, the cells were 
treated with increasing concentrations of Cisplatin. Surprisingly, compared with the 
control cell clones, ch-TOG/CKAP5 knockdown HCT116-CHK2-/- cells were more 
resistant towards Cisplatin treatment (Figure 3-9a). When treated with 0.2 μM 
Cisplatin, the mean area of the ch-TOG/CKAP5 knockdown cell colonies was 
1.23-fold greater than the control cells, 1.41-fold greater when treated with 0.4 μM 
Cisplatin, and 1.60-fold greater when treated with 0.8 μM Cisplatin (Figure 3-9a). In 
contrast, stable ch-TOG/CKAP5 knockdown cells derived from SW620 cells showed 
increased sensitivity towards Cisplatin (Figure 3-9b). The area of ch-TOG/CKAP5 
knockdown cell colonies was 1.46-fold lower than the control cells when treated with 
0.4 μM Cisplatin, and 1.33-fold lower when treated with 0.8 μM Cisplatin in SW620 
cells (Figure 3.9b). Thus, knockdown of ch-TOG/CKAP5 shows different effects 
towards Ciplatin treatment in HCT116-CHK2-/- and SW620 cells. 
 






Figure 3-9 Quantification of the area of cell colonies of 
HCT116-CHK2-/--shch-TOG and SW620-shch-TOG cell clones treated with 
different concentrations of Cisplatin. 
(a) Two independent shRNA control single cell clones and two independent 
sh-chTOG clones from HCT116-CHK2-/- were treated with increasing concentrations 
of Cisplatin, and the area of the cell colonies was determined after ten days. (b) Two 
indenpent shRNA control single cell clones and two independent sh-chTOG clones 
derived from SW620 were treated with increasing concentrations of Cisplatin, and the 
area of the cell colonies was determined after ten days. The areas of the cell colonies 
were normalized to control scrambled cells and represented as bar graphs (mean ± 
sem., t-test, n=3 independent experiments, ns = not significant). 
 





3.2. Drug responses towards other chemotherapeutic drugs in cells 
exhibiting CIN and after suppression of CIN 
After evaluating the CIN-dependent drugs responses towards platinum compounds, 
the cellular response towards various other chemotherapeutic drugs that are used for 
the treatment of CRC were also investigated. 
In fact, 5-FU is used as a single drug treatment or combined with other 
chemotherapeutic drugs in CRC treatment (Longley et al. 2003). Adriamycin has 
exhibited a broad spectrum of anti-tumor effect, particular against solid cancers 
including CRC (Myers et al. 1977). Irinotecan has anti-tumor activity against CRC 
and is used as the first- line treatment or after the failure of 5-FU or Oxaliplatin as a 
second- line treatment (Pitot et al. 1997; Rougier et al. 1997; Saltz et al. 2000). Two 
independent single cell clones of HCT116-CHK2-/- and SW620 described in Figure 
3-1 were treated with increasing concentrations of 5-FU, Adriamycin, and Irinotecan 
and the cellular response were evaluated by colony formation assays. 
The assays in the continuous presence of 5-FU, Adriamycin, and Irinotecan treatment 
revealed no differences in drug sensitivity in two independent cell clones of 
HCT116-CHK2-/- or SW620 cells in the presence or absence of Taxol (Figure 3-10, 
3-11, and 3-12).  






Figure 3-10 Quantification of the area of cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentrations of 5-FU in the presence or 
absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of 5-FU in the presence or absence of 0.5 nM Taxol and the area of the 
cell colonies was determined after ten days. (b) Cells of HCT116-CHK2-/- single cell 
clone 2 were treated with increasing concentrations of 5-FU in the presence or 
absence of 0.5 nM Taxol and the area of the cell colonies was determined after ten 
days. (c) Cells of SW620 single cell clone 1 were treated with increasing 
concentrations of 5-FU in the presence or absence of 0.5 nM Taxol and the area of the 
cell colonies was determined after ten days. (d) Cells of SW620 single cell clone 2 
were treated with increasing concentrations of 5-FU in the presence or absence of 0.5 
nM Taxol and the area of the cell colonies was determined after ten days. The areas of 
the cell colonies were normalized to control treated cells and represented as bar 
graphs (mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 






Figure 3-11 Quantification of the area cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentrations of Adriamycin in the presence 
or absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of Adriamycin in the presence or absence of 0.5 nM Taxol and the area 
of the cell colonies was determined after ten days. (b) Cells of HCT116-CHK2-/- 
single cell clone 2 were treated with increasing concentrations of Adriamycin in the 
presence or absence of 0.5 nM Taxol and the area of the cell colonies was determined 
after ten days. (c) Cells of SW620 single cell clone 1 were treated with increasing 
concentrations of Adriamycin in the presence or absence of 0.5 nM Taxol and the area 
of the cell colonies was determined after ten days. (d) Cells of SW620 single cell 
clone 2 were treated with increasing concentrations of Adriamycin in the presence or 
absence of 0.5 nM Taxol and the area of the cell colonies was determined after ten 
days. The areas of the cell colonies were normalized to control treated cells and 
represented as bar graphs (mean ± sem, t-test, n=3 independent experiments, ns = not 
significant). 
 






Figure 3-12 Quantification of the area of cell colonies for HCT116-CHK2-/- and 
SW620 cells treated with different concentration of Irinotecan in the presence or 
absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of Irinotecan in the presence or absence of 0.5 nM Taxol and the area 
of the cell colonies was determined after ten days. (b) Cells of HCT116-CHK2-/- 
single cell clone 2 were treated with increasing concentrations of Irinotecan in the 
presence or absence of 0.5 nM Taxol and the area of the cell colonies was determined 
after ten days.  (c) Cells of SW620 single cell clone 1 were treated with increasing 
concentrations of Irinotecan in the presence or absence of 0.5 nM Taxol and the area 
of the cell colonies was determined after ten days. (d) Cells of SW620 single cell 
clone 2 were treated with increasing concentrations of Irinotecan in the presence or 
absence of 0.5 nM Taxol and the area of the cell colonies was determined after ten 
days. The areas of the cell colonies were normalized to control treated cells and 
represented as bar graphs (mean ± sem., t-test, n=3 independent experiments, ns = not 
significant). 
 





I also investigated the effect of short-time removal of Taxol (Figure 3-1) for 5-FU, 
Adriamycin, and Irinotecan treatment in HCT116-CHK2-/- and SW620 cell clones. 
Again, no differences were observed (Figure 3-13, 3-14, and 3-15). 
 
Figure 3-13 Quantification of the area of cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentration of 5-FU in the presence or 
short-term absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of 5-FU in the presence or absence of 0.5 nM Taxol during the assay, 
and the area of the cell colonies was determined after ten days. (b) Cells of 
HCT116-CHK2-/- single cell clone 2 were treated with increasing concentrations of 
5-FU in the presence or absence of 0.5 nM Taxol during the assay and the area of the 
cell colonies was determined after ten days. (c) Cells of SW620 single cell clone 1 
were treated with increasing concentrations of 5-FU in the presence or absence of 0.5 
nM Taxol during the assay, and the area of the cell colonies was determined after 10 
days. (d) Cells of SW620 single cell clone 2 was treated with increasing 
concentrations of 5-FU in the presence or absence of 0.5 nM Taxol during the assay, 
and the area of the cell colonies was determined after ten days. The areas of the cell 





colonies were normalized to control treated cells and represented as bar graphs (mean 
± sem., t-test, n=3 independent experiments, ns = not significant). 
 
 
Figure 3-14 Quantification of the area of cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentrations of Adriamycin in the presence 
or short-time absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with increasing 
concentrations of Adriamycin in the presence or absence of 0.5 nM Taxol during the 
assay, and the area of the cell colonies was determined after ten days. (b) Cells of 
HCT116-CHK2-/- single cell clone 2 were treated with increasing concentrations of 
Adriamycin in the presence or absence of 0.5 nM Taxol during the assay, and the area 
of the cell colonies was determined after ten days.  (c) Cells of SW620 single cell 
clone 1 were treated with increasing concentrations of Adriamycin in the presence or 
absence of 0.5 nM Taxol during the assay, and the area of the cell colonies was 
determined after ten days. (d) Cells of SW620 single cell clone 2 were treated with 
increasing concentrations of Adriamycin in the presence or absence of 0.5 nM Taxol 
during the assay, and the area of the cell colonies was determined after ten days. The 





areas of the cell colonies were normalized to control treated cells and represented as 
bar graphs (mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 
 
Figure 3-15 Quantification of area of cell colonies of HCT116-CHK2-/- and 
SW620 cells treated with different concentration of Irinotecan in the presence or 
short-term absence of low-dose of Taxol. 
(a) Cells of HCT116-CHK2-/- single cell clone 1 were treated with different 
concentrations of Irinotecan in the presence or absence of 0.5 nM Taxol during the 
assay and the area of the cell colonies was determined after ten days. (b) Cells of 
HCT116-CHK2-/- single cell clone 2 were treated with increasing concentrations of 
Irinotecan in the presence or absence of 0.5 nM Taxol during the assay and the area of 
the cell colonies was determined after ten days. (c) Cells of SW620 single cell clone 1 
were treated with increasing concentrations of Irinotecan in the presence or absence 
of 0.5 nM Taxol during the assay and the area of the cell colonies was determined 
after ten days. (d) Cells of SW620 cell clone 2 were treated with increasing 
concentrations of Irinotecan in the presence or absence of 0.5 nM Taxol, and the area 
of the cell colonies was determined after ten days. The areas of the cell colonies were 





normalized to control treated cells and represented as bar graphs (mean ± sem., t-test, 
n=3 independent experiments, ns = not significant). 
 
 
Figure 3-16 Analyses of the acute response towards different high concentrations 
of 5-FU treatment in cells of HCT116-CHK2-/- Clone 1 in the presence or absence 
of Taxol. 
(a) DNA content profiles of HCT116-CHK2-/- in the presence or absence of low-does 
Taxol after 48 h of 5-FU treatment. (b) The proportion of cells with a Sub-G1 DNA 
content after 48 h different concentrations of 5-FU treatment was determined. (n=1 
experiment) 
 






Figure 3-17 Analyses of the acute response towards different high concentrations 
of Adriamycin in cells of HCT116-CHK2-/- clone 1 in the presence or absence of 
Taxol. 
(a) DNA content profiles of HCT116-CHK2-/- cells in the presence or absence of 
low-does Taxol after 48 h of Adriamycin treatment. (b) The proportion of cells with a 
Sub-G1 DNA content after 48 h different concentrations of Adriamycin treatment was 
determined. (n=1 experiment) 
 
Finally I investigated the acute response towards 5-FU and Adriamycin in 
HCT116-CHK2-/- cells by FACS analyses. Also, these experiments showed no 










































significant differences in the cellular response towards higher concentrations of 5-FU 
or Adriamycin treatment (Figure 3-16 and 3-17). 
 
In sum, suppression of CIN does not cause drug response differences towards other 
chemotherapeutic drugs such as 5-FU, Adriamycin, or Irinotecan. 
 
 
3.3. Drug responses in chromosomally stable CRC cells and after 
induction of CIN by DNA replication stress. 
 
3.3.1. Induction of CIN by Aphidicolin treatment in HCT116 cells. 
 
Figure 3-18 Aphidicolin induces CIN in chromosomally stable HCT116 cells. 
(a) Karyotype analysis by chromosome counting of metaphase spreads of single cell 
clones derived from HCT116 cells treated with DMSO, 1 or 2 ng/ml Aphidicolin for 
30 generations (n=50 cells). (b) The percentage of cells with chromosome numbers 
deviating from the modal were calculated.  
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Aphidicolin is a reversible inhibitor of the DNA polymerase α and thus, inhibits 
proper DNA replication during S phase, thereby inducing replication stress (Ikegami 
et al. 1978). Since replication stress was associated with numerical aneuploidy 
(Burrell et al. 2013), I tested whether low-dose Aphidicolin treatment is sufficient to 
induce CIN. For this, HCT116 cells were treated with DMSO (control) or with two 
concentrations of Aphidicolin (1 and 2 ng/ml). Single cell clones were grown for 30 
generations. Subsequently, the number of chromosomes per cell were determined by 
chromosome counting in metaphase spreads. The proportion of cells with 
chromosome numbers deviating from the modal (45 chromosomes) was analyzed.  
 
 
3.3.2. Inducing CIN by Aphidicolin does not cause response differences towards 
Oxaliplatin or Cisplatin treatment in HCT116 cells. 
To investigate whether induction of CIN upon replication stress would affect drug 
response in CRC cells, I used two HCT116 single cell clones that were either treated 
with DMSO or 2 ng/ml Aphidicolin. Colony formation assays in the continuous 
presence of Oxaliplatin or Cisplatin showed no significant response differences 
between Aphidicolin and DMSO treated HCT116 cells (Figure 3-19). These results 
indicate that acute induction of CIN in chromosomally stable CRC cell by replication 
stress is not sufficient to alter drug sensitivities towards Oxaliplatin or Cisplatin. 
 






Figure 3-19 Quantification of the area of cell colonies after treatment with 
different concentration of Oxaliplatin or Cisplatin in Aphidicolin- and 
DMSO-treated single cell clones. 
(a) Two independent DMSO-treated control single cell clones and two independent 2 
ng/ml Aphidicolin- treated single cell clones of HCT116 cells were treated with 
increasing concentrations of Oxaliplatin, and the area of the cell colonies was 
determined after ten days. (b) Two independent DMSO-treated control single cell 
clones and two independent 2 ng/ml Aphidicolin-treated single cell clones of HCT116 
cells were treated with increasing concentrations of Cisplatin, and the area of the cell 
colonies was determined after ten days. The areas of the cell colonies were 
normalized to control treated cells and represented as bar graphs (mean ± sem., t-test, 
n=3 independent experiments, ns = not significant). 





3.3.3. Short-term removal of Aphidicolin does not affect the drug response 
towards Oxaliplatin treatment, but increases resistance towards Cisplatin 
treatment in one single cell clone. 
 
 
Figure 3-20 Quantification of the area of cell colonies of Aphidicolin treated cells 
treated with different concentration of Oxaliplatin or Cisplatin in the presence 
or absence of Aphidicolin. 
(a) Cells of single cell clone 1 derived from 2 ng/ml Aphidicolin treated  HCT116 
cells were treated with increasing concentrations of Oxaliplatin in the presence or 
absence of Aphidicolin during the assay, and the area of the cell colonies was 
determined after ten days. (b) Cells of single cell clone 2 derived from 2 ng/ml 
Aphidicolin treated HCT116 cells were treated with increasing concentrations of 
Oxaliplatin in the presence or absence of Aphidicolin during the assay, and the area of 
the cell colonies was determined after ten days. (c) Cells of single cell clone 1 derived 
from 2 ng/ml Aphidicolin treated HCT116 cells were treated  with increasing 
concentrations of Cisplatin in the presence or absence of Aphidicolin during the assay, 
and the area of the cell colonies was determined after ten days. (d) Cells of single cell 
clone 2 derived from 2 ng/ml Aphidicolin treated HCT116 cells were treated with 





increasing concentrations of Cisplatin in the presence or absence of aphidicolin during 
the assay, and the area of the cell colonies was determined after ten days. The areas of 
the cell colonies were normalized to control treated cells and represented as bar 
graphs (mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 
Removal of Aphidicolin during the colony formation assay is expected to reveal 
whether ongoing chromosome missegregation or aneuploidy itself would affect drug 
response. On the other hand, it could also show whether Aphidicolin itself impacts on 
the drug response. Hence, I used two aneuploid single cell clones of 2 ng/ml 
Aphidicolin treated HCT116 cells and treated them with increasing concentrations of 
Oxaliplatin or Cisplatin in the presence or absence of Aphidicolin during the assay.  
These colony formation assays showed that upon Oxaliplatin treatment, no response 
differences were observed in the presence or absence Aphidicolin during the assay 
(Figure 3-20a and 3-20b). Upon Cisplatin treatment, single cell clone 1 derived from 
Aphidicolin treated cells showed a slightly higher resistant towards two 
concentrations of Cisplatin (0.8 and 1.6 μM) in the absence of Aphidicolin during the 
assay when compared to in the presence of Aphidicolin (Figure 3-20c). However, 
using a second single clone derived from Aphidicolin treated HCT116 cells, no 
significant differences were detectable towards Cisplatin treatment in the presence or 
absence of Aphidicolin during the assay (Figure 3-20d), indicating that the observed 
slight effect is not representative. 
Together, induction of CIN by Aphidicolin- triggered replication stress does not affect 
the cellular response towards Oxaliplatin or Cisplatin. 
 
3.4. Drug response in chromosomally stable CRC cells and after 
induction of CIN by treatment with a Mps1 inhibitor. 
 
3.4.1. Pharmacological inhibition of the mitotic spindle assembly checkpoint as 
a strategy to induce CIN. 
The Mps1 kinase plays a critical role in SAC signaling (Abrieu et al. 2001). 
Inhibition of the Mps1 kinase with the small molecular inhibitor MPS1-IN-3 causes 
chromosomal misalignment, and inhibition of the spindle checkpoint and thus, leads 





to chromosome missegregation and aneuploidy (Tannous et al. 2013). To induce CIN 
in chromosomally stable HCT116 cells, cells were treated with 0.5 μM MPS1-IN-3 or 
treated with DMSO as a control. Single cell clones were grown for 30 generations of 
treatment and the chromosome numbers were analyzed by chromosome counting. 
Subsequently, the proportion of cells with chromosome numbers deviating from the 
modal was determined. These analyses showed, as expected, that 0.5 μM MPS1-IN-3 
treated cells had a higher karyotype variability than the control treated cells, with a 
proportion of deviating from the modal from ~20% to 45-52% (Figure 3-21). Thus, 
treatment of HCT116 cells with the MPS1-IN-3 causes transient induction of CIN 
during inhibitor treatment. 
 
 
Figure 3-21 Treatment with the MPS1 inhibitor MPS1-IN-3 exhibits CIN. 
(a) Karyotype analysis by chromosome counting in metaphase spreads of the 
indicated single cell clones derived from HCT116 cells treated with DMSO or 0.5 μM 
MPS1-IN-3 for 30 generations (n=50 cells). (b) The percentage of cells with 
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3.4.2. Induction of CIN mediated by Mps1 inhibitor does not result in drug 
response differences towards Oxaliplatin or Cisplatin treatment in 
HCT116 cells. 
 
Figure 3-22 Quantification of the area of cell colonies of MPS1-IN-3 and 
DMSO-treated HCT116 cells treated with different concentration of Oxaliplatin 
or Cisplatin. 
(a) Two independent DMSO-treated control single cell clones and two separate 0.5 
μM MPS1-IN-3-treated single cell clones derived from HCT116 cells were treated 
with increasing concentrations of Oxaliplatin, and the area of the cell colonies was 
determined after ten days. (b) Two independent DMSO-treated control single cell 
clones and two independent 0.5 μM MPS1-IN-3-treated single cell clones from 
HCT116 cells were treated with increasing concentrations of Cisplatin, and the area of 
the cell colonies was determined after ten days. The areas of the cell colonies were 
normalized to control treated cells and represented as bar graphs (mean ± sem., t-test, 
n=3 independent experiments, ns = not significant). 






To investigate whether induction of CIN by inhibition of the Mps1 kinase would 
affect drug responses in CRC cells, I used two independent single cell clones derived 
from 0.5 μM MPS1-IN-3 or DMSO treated HCT116 cells. These cell clones were 
treated with various concentrations of Oxaliplatin or Cisplatin and colony formation 
assays were performed. These analyses showed no significant differences in drug 
response towards Oxaliplatin (Figure 3-22a) or Cisplatin (Figure 3-22b) 
Thus, induction of CIN by inhibition of the spindle assembly checkpoints in 
chromosomally stable CRC cells does not affect the drug responses towards 
Oxaliplatin or Cisplatin. 
 
 
3.4.3. Short-term removal of MPS1-IN-3 does not result in drug response 
differences towards Oxaliplatin, but increases the resistance towards 
Cisplatin in one cell clone. 
As treatment with Mps1 inhibitor induces CIN transiently, removal of MPS1-IN-3 is 
expected to reduce ongoing chromosome missegregation in cells. Hence, the two 
single cell clones of MPS1-IN-3 treated HCT116 cells were treated with different 
concentrations Oxaliplatin or Cisplatin in the presence or absence of MPS1-IN-3 and 
colony formation assays were performed.  
These analyses showed that upon Oxaliplatin treatment, no significant response 
differences were detectable in the presence or absence MPS1-IN-3 during the assay 
(Figure 3-23a and 3-23b). Upon Cisplatin treatment, two concentrations of Cisplatin 
(0.8 and 1.6 μM) were slightly more resistant in the absence of MPS1-IN-3 during the 
assay in the first MPS1-IN-3 treated single cell clone (Figure 3.23c). However, using 
the second MPS1-IN-3 treated single cell clone of HCT116, no significant differences 
were found (Figure 3-23d).  






Figure 3-23 Quantification of the area of cell colonies of MPS1-IN-3 treated cells 
treated with different concentration of Oxaliplatin or Cisplatin in the presence 
or absence of MPS1-IN-3. 
(a) Cells of MPS1-IN-3 treated clone 1 from HCT116 cells were treated with 
increasing concentrations of Oxaliplatin in the presence or absence of MPS1-IN-3, 
and the area of the cell colonies was determined after ten days. (b) Cells of 
MPS1-IN-3 treated clone 2 from HCT116 cells was treated  with increasing 
concentrations of Oxaliplatin in the presence or absence of MPS1-IN-3, and the area 
of the cell colonies was determined after ten days. (c) Cells of MPS1-IN-3 treated 
clone 1 from HCT116 cells were treated with increasing concentrations of Cisplatin in 
the presence or absence of MPS1-IN-3, and the area of the cell colonies was 
determined after ten days. (d) Cells of MPS1-IN-3 treated clone 1 from HCT116 cells  
were treated with increasing concentrations of Cisplatin in the presence or absence of 
MPS1-IN-3, and the area of the cell colonies was determined after ten days. The areas 
of the cell colonies were normalized to control treated cells and represented as bar 
graphs (mean ± sem., t-test, n=3 independent experiments, ns = not significant). 
 





Hence, induction of replication stress by Aphidicolin and inhibition of Mps1 are 
sufficient to cause CIN in chromosomally stable CRC cells. However, inducing of 
CIN by these two means does not result in drug response differences towards 

























4.1. Drug responses towards commonly used chemotherapeutic 
drugs in CRC cells exhibiting CIN and after suppression of 
CIN. 
The aim of my study was to investigate whether chromosomal instability (CIN) is 
causally related to differential drug responses in colorectal cancer cells. For this, I 
used two different cell systems based on CHK2 deficient HCT116 cells and on 
SW620 cells that are both chromosomally unstable. In both cases, previous work from 
our lab has established that the CIN phenotype and thus, perpetual chromosome 
missegregations during mitosis are triggered by an increase in microtubule dynamics. 
Intriguingly, this defect can be corrected, e.g. by treatment of the cells with low doses 
of Taxol or by partial repression of the microtubule polymerase ch-TOG/CKAP5 
(Ertych et al. 2014). Therefore, I was able to directly compare the drug responses in 
individual single cell clones that were grown either in the absence or in the presence 
of Taxol or upon repression ch-TOG/CKAP5. 
During the course of my work, I found that HCT116-CHK2-/- cells that grew in the 
absence of Taxol were more resistant toward Oxaliplatin compared to cells growing 
in the presence of Taxol (Figure 3-2a and 3-2b). Even short-term removal of Taxol 
had a similar effect (Figure 3-3a, and 3-3b). This might indicate that ongoing 
chromosome missegregations during mitosis may cause drug resistance, which is not 
dependent on karyotype evolvement over longer periods of time. Similarly, partially 
repression of ch-TOG/CKAP5 caused a higher sensitivity towards Oxaliplatin in 
HCT116-CHK2-/- cells (Figure 3-4a), which might further confirm that ongoing 
chromosome missegregation during mitosis causes drug resistance. 
Regarding the immediate response towards higher concentrations of Oxaliplatin, no 
response differences were observed in the presence or absence of Taxol (Figure 3-5). 
Since chromosome missegregation occurs only in 20%-50% CIN cells per cell cycle 
(Lengauer et al. 1997; Thompson and Compton 2008), this might not be sufficient to 
result in drug response differences between CIN cells and cells where CIN was 
suppressed.  





In contrast to CHK2 knockout HCT116 cells, no drug response differences towards 
Oxaliplatin were observed in two independent clones of SW620 cells that were grown 
in the presence or absence of Taxol (Figure 3-2c, 3-2d, 3-3c and 3.3d), although also 
in these cells a suppression of CIN in response to Taxol treatment have been 
established (Ertych et al. 2014). The SW620 cells with partial repression of 
ch-TOG/CKAP5, however, seemed to be more sensitive towards Oxaliplatin (Figure 
3-4b). If we looked carefully into the drug response of the two independent clones of 
shch-TOG and shcontrol, the drug response of the two control clones was different. In 
this case, it is not possible to draw a clear conclusion that partially repression 
ch-TOG/CKAP5 in SW620 causes more sensitivity towards Oxaliplatin.  
Thus, while HCT116-CHK2-/- cells showed a decreased sensitivity towards 
Oxaliplatin that appears to be dependent on microtubule dynamics and/or CIN, this 
was not reproducible in SW620 cells. This might indicate that the suppression of 
chromosome missegregation in CHK2 deficient cells by low-dose of Taxol is more 
efficient than in SW620 cells. Since also the short-term removal of Taxol affects drug 
response, it might be that the acute chromosome missegregation determines the 
response towards Oxaliplatin. Another possibility is that the observed difference in 
the response towards Oxaliplatin might be specifically due to the loss of CHK2 rather 
than due to the presence of a CIN phenotype. Chk2 is a multifunctional kinase with 
known functions central to the induction of cell cycle arrest and apoptosis after DNA 
damage (Ahn et al. 2004; Antoni et al. 2007). Therefore, loss of CHK2 in the 
HCT116-CHK2-/- cells might directly affect the response towards various DNA 
damaging drugs including Oxaliplatin. However,  previous work showed that the 
loss of CHK2 does neither affect p53 activation nor the DNA damage response after 
5-FU-induced DNA damage (Jallepalli et al. 2003). It remains also unclear why Taxol 
treatment and partial repression of ch-TOG/CKAP5 would affect the drug response in 
CHK2 deficient cells. Nevertheless, my studies revealed that cancer cells with a loss 
of CHK2 expression can be sensitized towards Oxaliplatin treatment by co-treatment 
with subnanomolar concentrations of Taxol, which might represent an interesting 
addition to the current chemotherapeutic treatment scheme for the colorectal cancer. 
 





In contrast to Oxaliplatin, other chemotherapeutic drugs, including 5-FU, Adriamycin, 
and Irinotecan showed no drug response differences in two independent clones of 
HCT116-CHK2-/- or SW620 before or after CIN-suppression (Figure 3-10 - 3-16). 
This might indicate that chromosome missegregation caused drug resistance is 
specific to platinum compounds but the molecular reason for this remains unclear.  
To clarify whether the observed resistance is specific to Oxaliplatin, I investigated 
also the response towards a second platinum compound namely Cisplatin, which is 
also widely used in the clinic for cancer therapy. Surprisingly, no drug response 
differences for Cisplatin were detectable in HCT116-CHK2-/- or in SW620 in the 
presence or absence of Taxol (Figure 3-6 and 3-7). On the other hand, partially 
repression of ch-TOG/CKAP5, which suppressed CIN, caused an increasing resistance 
towards Cisplatin in HCT116-CHK2-/- (Figure 3-9a). For SW620 cells, the two 
independent control clones showed opposite response as exhibited in Oxaliplatin 
treatment (Figure 3-9b), which represent inconsistent results overall. 
Why is there such a difference in response towards two related platinum compounds? 
Both, Cisplatin and Oxaliplatin form DNA adducts. However, the structure of DNA 
adducts in response to Cisplatin and Oxaliplatin treatment are different (Figure 4-1) 
(Chaney et al. 2005).  
 
 
Figure 4-1 Selected platinum compounds and their DNA adducts. (from Chaney 
et al., 2005, p. 4) 






Because of the structural differences of the Platinum-DNA adducts, these two 
platinum compounds have different affinity to cellular proteins. Binding of the 
cellular proteins to the Platinum-DNA adducts increases the cytotoxicity of the DNA 
adducts. Several studies showed that Cisplatin-DNA adducts has higher affinity to 
mismatch repair proteins and some damage-recognition proteins (McLaughlin et al. 
1993; Wei et al. 2001). In contrast, Oxaliplatin-DNA adducts bypass translesion DNA 
polymerases, which determines whether the translesion synthesis is error-free or 
error-prone (Chaney et al. 2005). These differential outcomes of Cisplatin- and 
Oxaliplatin-DNA adducts are thought to contribute to the differences in cytotoxicity 
of Cisplatin and Oxaliplatin (Chaney et al. 2005), which might also explain why 
Cisplatin and Oxaliplatin showed entirely different responses regarding 
ch-TOG/CKAP5 suppression of HCT116-CHK2-/- cells. But it is still unclear why no 
response difference towards Cisplatin was observed in HCT116-CHK2-/- in the 
presence or absence of Taxol. 
 
4.2. Drug responses in chromosomally stable HCT116 cells and 
upon induction of CIN by replication stress or inhibition of the 
mitotic spindle assembly checkpoint. 
Aphidicolin is a specific inhibitor of DNA polymerase α, which is primarily involved 
in DNA replication (Ikegami et al. 1978). Thus, Aphidicolin triggers replication fork 
instability and leads to instability of particular genomic regions called common fragile 
sites (CFSs), which are susceptible to replication-stress- induced double-strand breaks 
(Durkin and Glover 2007; Mazouzi et al. 2016). A recent study revealed that 
Aphidicolin triggers universal changes in both gene expression and protein 
phosphorylation patterns (Mazouzi et al. 2016). My work showed that treatment with 
low-doses of Aphidicolin treatment caused mitotic chromosome missegregation and 
CIN in chromosomally stable HCT116 cells (F igure 3-18). I used this condition to 
investigate whether induction of CIN affects drugs responses in CRC cells. 
The second condition I used to induce CIN in chromosomally stable CRC cells was 
pharmacological inhibition of Mps1. Mps1 functions as an essential kinase that 
activates the spindle assembly checkpoint (SAC) to ensure proper segregation of 





sister chromatids onto the daughter cells. It was demonstrated that small molecule 
inhibitors for the Mps1 kinase cause chromosome missegregation due to disruption of 
the SAC, thereby inducing CIN (Janssen et al. 2011). By karyotype analysis, I found 
that the prolonged treatment of HCT116 cells with the MPS1-IN-3 inhibitor indeed 
caused CIN and whole chromosome aneuploidy (Figure 3-21). 
The mechanism of suppression of CIN by low-dose of Taxol or suppression of 
ch-TOG/CKAP5 is by restoring proper microtubule assembly rates (Ertych et al. 
2014). To compare the drug response between chromosomally stable and instable 
cells, other mechanisms leading to CIN were desired. Therefore, Aphidicolin and 
MPS1-IN-3 treated cells, both of which exhibiting CIN were used. However, after 
treatment with Oxaliplatin and Cisplatin, no drug response differences were observed 
between Aphidicolin or MPS1-IN-3-treated cells and control cells (Figure 3-19 and 
3-22). Removal of Aphidicolin or MPS1-IN-3 resulted in slight resistance towards 
Cisplatin in one cell clone (Figure 3-20c and 3-23c), but no response differences in 
the other cell clone (Figure 3-20d and 3-23d), which indicates that the observed effect 
is not representative. Thus, inducing CIN by replication stress triggered by 
Aphidicolin or disturbing the spindle assembly checkpoint by treatment with a Mps1 
inhibitor did not affect the drug response in HCT116 cells. While it cannot be 
excluded that the lack of response differences is specific for HCT116 cells, it might 
be desirable to investigate the induction of CIN in other cancer cell lines. 
 
In summary, my results revealed microtubule dynamics-dependent resistance towards 
Oxaliplatin only in CIN cells with CHK2 deficiency. Other CIN cells (e.g. SW620, 
chromosomally stable HCT116 cells treated by Aphidicolin or Mps1 inhibitor) did not 
show any response differences compared to non-CIN cells. These results are in 
contrast to a recent study by Lee et al. who showed that CIN is associated with 
multidrug resistance (Lee et al. 2011). The main difference between my study and 
Lee’s study is that I used single cell clones with only little cell-to-cell heterogeneity. 
Several studies have suggested that tumor heterogeneity is associated with drug 
resistance in patients (Marusyk and Polyak 2010; Turner and Reis-Filho 2012). 
Clonal analysis of CIN and non-CIN cells are likely responsible for reduced genetic 
heterogeneity within the cell populations. Therefore, my results might indicate that 





the CIN phenotype per se does not confer drug resistance, but that a high genetic 
heterogeneity within the cell population might contribute to altered drug responses.  
 
4.3. CHK2 deficiency: a key for resistance towards Oxaliplatin 
treatment? 
Since only chromosomally instable CHK2 deficient HCT116 cells showed a clear 
tendency of drug resistance towards Oxaliplatin, it seems plausible that the loss of   
CHK2 function itself that might contribute to drug resistance.  
 
Figure 4-2 The role of Chk2 in DNA damage response and mitosis regulation. 
(a) Upon DNA double strand breaks, the Chk2 kinase is activated by phosphorylation 
on threonine-68 by the ATM kinase. After homodimerization and 
trans-phosphorylation of threonine-383 and -387 located within the activation loop, 
the Chk2 kinase achieves its full activation. Subsequently, Chk2 can phosphorylate 
critical substrates such as Cdc25C, Cdc25A, p53, PML, E2F1 and Brca1, which is 
required to mediate cell cycle delay, cell cycle arrest, apoptosis and in response to 
DNA repair. (b) In the absence of DNA damage, the active Chk2 kinase can also 





phosphorylate Brca1 on serine-988 during mitosis, which promotes the proper 
assembly of the normal mitotic spindle. (from Stolz et al., 2011, p. 402) 
 
An important function of the Chk2 kinase is to operate downstream of ATM in 
response to DNA damage. Chk2 is phosphorylated at threonine-68 by the ATM 
kinase upon DNA double strand breaks (Ahn et al. 2004). After dimerization and full 
activation, the Chk2 kinase can mediate cell cycle arrest, apoptosis, and DNA repair 
through phosphorylating key substrates such as Cdc25C, Cdc25A, p53, PML, E2F1, 
and Brca1 (Figure 4-2a) (Stolz et al. 2011). In addition to DNA damage response, 
previous work from our lab also established Chk2 to be required for the maintenance 
of chromosomal stability during mitosis (Figure 4-2b). In fact, CHK2 deficiency 
induces CIN in chromosomally stable cells by increasing microtubule assembly rates 
(Ertych et al. 2014; Stolz et al. 2010) 
Cdc25C is a dual-specificity protein phosphatase that dephosphorylates Cdc2 thereby 
controlling the entry into mitosis (Peng et al. 1997). Upon DNA damage, Chk2 
phosphorylates Cdc25C on serine-216, which causes its inhibition. As a result, the 
cell cycle arrests at the G2/M transition (Matsuoka et al. 1998). Cdc25A can activate 
CDK2 that is needed for entry in S-phase and for DNA synthesis (Hoffmann et al. 
1994). However, in response to DNA damage, Chk2 phosphorylates Cdc25A on 
serine-123, which mediates Cdc25A ubiquitylation and is subsequent degradation, 
preventing the CDK2 activation at the G1/S transition (Falck et al. 2001; Jinno et al. 
1994).  
Previous studies revealed that CHK2 deficient mice exhibit radioresistance (Falck et 
al. 2001; Takai et al. 2002), and this resistance is mediated by the 
ATM-Chk2-Cdc25A checkpoint pathway (Falck et al. 2001). Oxaliplatin forms DNA 
adducts and thereby also causes DNA damage. Thus, radioresistance and resistance 
towards Oxaliplatin might be mechanistically related. However, it remains elusive 
why the differential drug response is alleviated upon restoration of normal 
microtubule dynamics. It is advised that the future studies will address this important 
question. 
Previous work from our lab also revealed that Chk2 activates Brca1 and thereby 
ensuring proper microtubule plus-end assembly and chromosomal stability during 





mitosis. Loss function of Chk2 results in Aurora-A to act as a negative regulator of 
Brca1 during mitosis (Ertych et al. 2016). Interestingly, a recent study found that 
Brca1 inactivation causes resistance towards Oxaliplatin in CRC (Moutinho et al. 
2014). Hence, Chk2 might act through Brca1 to regulate Oxaliplatin sensitivity. 
However, future work needs to address the underlying molecular mechanism leading 
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